Key clinical point: Descovy for PrEP is going to be a tough sell when generic Truvada hits the market.
Major finding: PrEP failed in just two men at high risk for HIV, one in the Descovy arm and one in the Truvada arm. The drugs were equally safe.
Study details: Randomized trial involving more than 5,000 men.
Disclosures: The work was funded by Gilead; four investigators, including the senior investigator, were employees. The presenter was an investigator for the company.
Hare CB et al. CROI 2019, Abstract 104 LB.